​

Insulet (PODD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PODD Stock Forecast

Insulet (PODD) stock forecast, based on 49 Wall Street analysts, predicts a 12-month average price target of $357.25, with a high of $435.00 and a low of $286.00. This represents a 49.95% increase from the last price of $238.24.

$150 $210 $270 $330 $390 $450 High: $435 Avg: $357.25 Low: $286 Last Closed Price: $238.24

PODD Stock Rating

Insulet stock's rating consensus is Buy, based on 49 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 36 Buy (73.47%), 10 Hold (20.41%), 3 Sell (6.12%), and 0 Strong Sell (0.00%).

Buy
Total 49 0 3 10 36 Strong Sell Sell Hold Buy Strong Buy

PODD Price Target Upside V Benchmarks

TypeNameUpside
StockInsulet49.95%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks27.71%

Price Target Trends

1M3M12M
# Anlaysts71425
Avg Price Target$339.57$354.00$364.68
Last Closing Price$238.24$238.24$238.24
Upside/Downside42.53%48.59%53.07%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 266181-126
Feb, 266181-126
Jan, 265192--26
Dec, 255182--25
Nov, 255173--25
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 19, 2026Truist Financial$360.00$246.0446.32%51.11%
Feb 19, 2026Evercore ISI$340.00$251.2135.34%42.71%
Feb 19, 2026David RomanGoldman Sachs$326.00$251.3829.68%36.84%
Feb 19, 2026Oppenheimer$300.00$254.5917.84%25.92%
Feb 19, 2026Bernstein$330.00$258.0727.87%38.52%
Feb 19, 2026Barclays$286.00$258.0710.82%20.05%
Feb 18, 2026William PlovanicCanaccord Genuity$435.00$258.0768.56%82.59%
Feb 04, 2026Stifel Nicolaus$350.00$249.0740.52%46.91%
Jan 12, 2026Barclays$274.00$286.92-4.50%15.01%
Jan 09, 2026Lee HambrightBernstein$380.00$292.8929.74%59.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 19, 2026Goldman SachsBuyBuyhold
Feb 19, 2026BarclaysUnderweightUnderweighthold
Feb 18, 2026Canaccord GenuityBuyBuyhold
Feb 18, 2026BTIGBuyBuyhold
Jan 26, 2026Cowen & Co.BuyHolddowngrade
Jan 12, 2026BarclaysEqual-WeightUnderweightdowngrade
Jan 09, 2026BernsteinOutperformOutperformhold
Jan 09, 2026Goldman SachsBuyBuyhold
Dec 18, 2025UBSBuyBuyhold
Dec 16, 2025Evercore ISIOutperforminitialise

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.25$0.07$2.96$5.97$3.51---
Avg Forecast$0.13$0.42$1.99$3.21$3.93$4.95$5.96$7.30
High Forecast$0.13$0.43$2.08$3.36$4.30$5.68$6.79$7.55
Low Forecast$0.13$0.41$1.86$3.11$3.71$3.58$4.76$7.08
Surprise %92.31%-83.33%48.74%85.98%-10.69%---

Revenue Forecast

$1B $2B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.10B$1.31B$1.70B$2.07B$2.71B---
Avg Forecast$1.09B$1.27B$1.65B$2.06B$2.43B$2.86B$3.32B$3.75B
High Forecast$1.11B$1.30B$1.69B$2.11B$2.49B$2.86B$3.35B$3.85B
Low Forecast$1.07B$1.24B$1.64B$2.05B$2.40B$2.85B$3.28B$3.67B
Surprise %0.66%2.88%2.96%0.71%11.33%---

Net Income Forecast

$-150M $0 $150M $300M $450M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.80M$4.60M$206.30M$418.30M$247.10M---
Avg Forecast$4.65M$-70.49M$206.30M$238.15M$289.34M$368.31M$434.07M$537.52M
High Forecast$17.25M$-30.76M$322.59M$247.32M$316.29M$418.31M$499.77M$555.71M
Low Forecast$-7.94M$-110.23M$90.01M$228.97M$273.53M$263.30M$350.38M$521.49M
Surprise %261.00%-106.53%-75.65%-14.60%---

PODD Forecast FAQ

Is Insulet stock a buy?

Insulet stock has a consensus rating of Buy, based on 49 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 36 Buy, 10 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Insulet is a favorable investment for most analysts.

What is Insulet's price target?

Insulet's price target, set by 49 Wall Street analysts, averages $357.25 over the next 12 months. The price target range spans from $286 at the low end to $435 at the high end, suggesting a potential 49.95% change from the previous closing price of $238.24.

How does Insulet stock forecast compare to its benchmarks?

Insulet's stock forecast shows a 49.95% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (27.71%).

What is the breakdown of analyst ratings for Insulet over the past three months?

  • March 2026: 23.08% Strong Buy, 69.23% Buy, 3.85% Hold, 0% Sell, 3.85% Strong Sell.
  • February 2026: 23.08% Strong Buy, 69.23% Buy, 3.85% Hold, 0% Sell, 3.85% Strong Sell.
  • January 2026: 19.23% Strong Buy, 73.08% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is Insulet’s EPS forecast?

Insulet's average annual EPS forecast for its fiscal year ending in December 2026 is $4.95, marking a 41.03% increase from the reported $3.51 in 2025. Estimates for the following years are $5.96 in 2027, and $7.3 in 2028.

What is Insulet’s revenue forecast?

Insulet's average annual revenue forecast for its fiscal year ending in December 2026 is $2.86B, reflecting a 5.51% increase from the reported $2.71B in 2025. The forecast for 2027 is $3.32B, and $3.75B for 2028.

What is Insulet’s net income forecast?

Insulet's net income forecast for the fiscal year ending in December 2026 stands at $368.31M, representing an 49.05% increase from the reported $247.1M in 2025. Projections indicate $434.07M in 2027, and $537.52M in 2028.